Oncostatin M protein
3x Oncostatin M protein found in fitzgerald
- Antibody SubtypeRecombinant Proteins
- Area of researchCytokines & Growth Factors
- Type of proteinRecombinant
- Expression SystemEscherichia coli
- Grade & PurityGrater than 98% pure
- Shipping conditionsBlue Ice
- Gene target
- Short nameOncostatin M protein
- Alternative nameOncostatin M protein
30R-AO009 | Oncostatin M proteinsize: 10 µg | 400.74 USD
30R-AO002 | Oncostatin M proteinsize: 10 µg | 400.74 USD
- Catalog number30R-AO002
- Price400.74 USD
- Size10 µg
- ResiduesRegion of Oncostatin M protein corresponding to amino acids MAAIGSCSKE YRVLLGQLQK QTDLMQDTSR LLDPYIRIQG LDVPKLREHC RERPGAFPSE ETLRGLGRRG FLQTLNATLG CVLHRLADLE QRLPKAQDLE RSGLNIEDLE KLQMARPNIL GLRNNIYCMA QLLDNSDTAE PTKAGRGASQ PPTPTPASDA FQRKLEGCRF LHGYHRFMHS VGRVFSKWGE SPNRSRRHSP HQALRKGVRR TRPSRKGKRL MTRGQLPR.
- Form & BufferProvided as a lyophilized powder. Reconstitute in water to a concentration of 0.1-1.0 mg/ml.
- StorageStore at 4 deg C until reconstitution. Following reconstitution aliquot and freeze at -20 deg C for long term storage. Avoid repeated freeze/thaw cycles.
- Tested forPlease refer to the datasheet
- BioactivityThe ED50 as determined by the dose-dependent stimulation of the proliferation of human TF-1 cells is approximately 2 ng/ml, corresponding to a specific activity of approximately 5 x 10^5 units/mg.
- ConceptRegistry number:106956-32-5Scope note:A cytokine with both pro- and anti-inflammatory actions that depend upon the cellular microenvironment. Oncostatin M is a 28 kDa monomeric glycoprotein that is similar in structure to LEUKEMIA INHIBITORY FACTOR. Its name derives from the the observation that it inhibited the growth of tumor cells and augmented the growth of normal fibroblasts.CASN1 number:Oncostatin M
- Tree numbers
- Qualifiersimmunology, pharmacokinetics, biosynthesis, physiology, therapeutic use, secretion, toxicity, poisoning, administration & dosage, adverse effects, agonists, blood, cerebrospinal fluid, chemical synthesis, contraindications, deficiency, chemistry, drug effects, urine, radiation effects, history, analysis, antagonists & inhibitors, classification, economics, genetics, isolation & purification, metabolism, pharmacology, standards, supply & distribution, ultrastructure
- PubMedWe conclude that an OSMR/TGM2/integrin-alpha5beta1/fibronectin pathway is of biological significance in cervical squamous cell carcinomasOSMR is able to bind OSM and interleukin-31 when associated to soluble gp130 or soluble interleukin-31R, respectively, and to neutralize both cytokine propertiesmurine OSMR initiates STAT5 activation directly via the receptor bound Janus kinases. Intriguingly, the murine receptor preferentially recruits JAK2, whereas the human receptor seems to have a higher affinity for JAK1.study reporta a Japanese family with familial primary localized cutaneous amyloidosis in whom a novel OSMR mutation was observedstudy provides evidence for the existence of a novel pathogenic mutation in the OSMR gene in a caucasian family with familial primary cutaneous amyloidosisThe identification of OSMR and IL31RA gene pathology provides an explanation of the high prevalence of primary cutaneous amyloidosis in Taiwan as well as new insight into disease pathophysiology.We conclude that OSMR overexpression in cervical SCC cells provides increased sensitivity to OSM, which induces pro-malignant changes.this study offers new findings on the molecular genetics and disease relevance of mutations in OSMR in Familial primary localized cutaneous amyloidosis.
- Gene ontology - Biological process
- Gene ontology - Cellular component
- Gene ontology - Molecular function
- Entrez Gene
30R-2605 | Oncostatin M proteinsize: 10 µg | 431.38 USD